When better still might not be good enough
Open Access
- 1 October 2017
- journal article
- editorial
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 6 (S7) , S1244-S1247
Abstract
When better still might not be good enoughKeywords
This publication has 26 references indexed in Scilit:
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of IbrutinibJournal of Clinical Oncology, 2017
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyNew England Journal of Medicine, 2016
- Glioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient PrognosisPLOS ONE, 2013
- EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma MultiformeCancer Cell, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Interleukin-15 biology and its therapeutic implications in cancerTrends in Pharmacological Sciences, 2012
- EphA2 as a Novel Molecular Marker and Target in Glioblastoma MultiformeMolecular Cancer Research, 2005
- Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.2002
- Mutants of Interleukin 13 with Altered Reactivity toward Interleukin 13 ReceptorsJournal of Biological Chemistry, 1999
- An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link.1998